IngentaConnect Circulating type I collagen degradation products: a new serum mar...

Authors: Hunzelmann¹; Risteli^{2, 2}; Sacher¹; Vancheeswaran³; Black³; Krieg¹

Source: British Journal of Dermatology, Volume 139, Number 6, December 1998 , pp. 1020-1025(6)

Abstract:

Systemic sclerosis (SSc; scleroderma) results in the excessive deposition of extracellular matrix components in affected organs. This is partly due to enhanced synthesis; however, the role of degradative processes in this disease is still poorly understood. Sera of 32 patients with SSc (22 with the diffuse, 10 with the limited form) and of six patients with morphoea were assessed using radioimmunoassays for the cross-linked carboxy terminal telopeptide of type I collagen (ICTP) and for the amino terminal propeptide of type I procollagen (PINP) reflecting type I collagen degradation and synthesis, respectively. In 27 of the 32 patients with SSc, the concentration of ICTP was above the upper limit of the normal value (4.6 μg/L) and the mean level was clearly elevated at 7.92 μg/L. The ICTP concentration correlated with the skin score measuring the extent of the lesions, whereas no such correlation was found for PINP. The ICTP antigen in serum, studied by immunoblotting, had a molecular weight of about twice that of the trypsin-generated fragment isolated from human bone collagen. The mean concentration of serum PINP was 43.9 μg/L and no patient exceeded the upper limit of the normal range (80 μg/L).We report here for the first time that the concentration of the type I collagen degradation product ICTP in serum shows a close correlation with the extent of skin fibrosis in patients with SSc. We conclude that the increased deposition of type I collagen in this disease is accompanied by an increased turnover of this molecule, indicating a more complex derangement of synthetic and degradative processes than previously acknowledged.

Document Type: Original article

DOI: 10.1046/j.1365-2133.1998.02558.x

Affiliations: 1: Department of Dermatology, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany, 2: Departments of Medical Biochemistry and Clinical Chemistry, University of Oulu, Oulu, Finland, 3: Department of Rheumatology, The Royal Free Hospital, London NW3 2QG, U.K.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma?